Largest gene therapy trial for cystic fibrosis begins
The trial will see patients 'breathe in' the gene therapy using a nebulizer.
(Medical Xpress) -- British scientists are to carry out the largest trial anywhere in the world of a gene therapy for cystic fibrosis.
A consortium of researchers from Oxford University, Imperial College London and the University of Edinburgh will start enrolling patients on the trial this month.
The UK Cystic Fibrosis Gene Therapy Consortium hopes that the study will show for the first time whether the gene therapy they have developed can improve the health of patients. The phase two clinical trial will involve 130 cystic fibrosis patients using an inhaler to breathe in a working copy of the cystic fibrosis gene once a month for a year.
The trial will go ahead thanks to £3 million in funding from the Medical Research Council (MRC) and the National Institute for Health Research (NIHR) that is announced today.
Additional laboratory studies to develop a potentially more efficient delivery method for the gene therapy will receive a further £1.2 million in support from the MRC.
"No one has ever done a gene therapy study like this in cystic fibrosis before," said Dr. Deborah Gill of the Nuffield Department of Clinical Laboratory Sciences at Oxford University. "Its a worldwide first in terms of the length of the study, the number of patients involved and the number of doses of gene therapy. By giving the therapy over a whole year, we will have the best chance yet of seeing an improvement in patients."
Professor Eric Alton, the coordinator for the consortium from Imperial College London, said: 'Conventional treatments have extended the life expectancy for people with cystic fibrosis. Were hoping that this therapy will achieve a step change in the treatment of cystic fibrosis that focuses on the basic defect rather than just addressing the symptoms.
"This trial will assess if giving gene therapy repeatedly for a year will lead to the patients' lungs getting better. Eventually we hope gene therapy will push cystic fibrosis patients towards a normal life expectancy and improve their quality of life significantly."
Cystic fibrosis is an inherited disease that affects around 9,500 people in the UK. There is currently no cure and the only available treatments rely on alleviating the symptoms, not treating the underlying cause. The average life expectancy for cystic fibrosis patients is only 35 years.
The disease is caused by a single faulty gene that leads to thick, sticky mucus to build up in the lungs and digestive system.
The researchers in the UK Cystic Fibrosis Gene Therapy Consortium have developed a successful method for delivering a working copy of the defective gene directly into the lungs of patients.
The gene is administered via a nebulizer much like inhalers used in asthma. Patients simply inhale a fine mist of fat globules which carry the DNA for the gene wrapped up inside.
The researchers have previously shown in smaller-scale clinical trials that their nebulizer approach can get a working copy of the cystic fibrosis gene into the cells of the lung, and that the gene continues to work for a period of weeks and months.
The new clinical trial will assess whether the gene therapy can provide measurable clinical benefits for people with cystic fibrosis. That is: whether it can actually improve peoples lung function, and reduce the amount of mucus, inflammation and infection seen in patients.
Patients will be seen at the Royal Brompton Hospital, London, and the Western General Hospital and the Royal Hospital for Sick Children, Edinburgh.
The second lab-based study, with a further £1.2 million in funding from the MRC, will investigate a potentially more efficient delivery method for the gene therapy. The aim is to use a modified virus to carry the replacement gene into the lungs, which could lead to an even more effective treatment in the future.
Dr. Gill said: "The new virus delivery approach has never been tried before but it could be more efficient. It is specifically designed to deliver the gene therapy to the lungs, but it will take several more years of development before it gets to the point of human trials."
The consortiums research, which has been supported by the Cystic Fibrosis Trust for a decade, had faced an uncertain future due a funding shortfall. The new funding from the MRC and NIHR will ensure the next stage of the research can continue as planned.
Professor Eric Alton of Imperial College London said: "With funding for this key part of the consortium's program secure, we will begin preparations for the trial immediately."
Dr. Gill said: "A lot of cystic fibrosis patients in this country have either been directly involved in trials or in fundraising to support the research. That this new trial is going ahead is a really great result for everyone. It could find out if gene therapy has a chance of working for all cystic fibrosis patients."
Provided by Oxford University
- Breathe deep: Which patients could benefit from inhaled steroids in cystic fibrosis? Nov 29, 2007 | not rated yet | 0
- Scientists develop first ever drug to treat 'Celtic gene' in cystic fibrosis sufferers Jun 20, 2011 | not rated yet | 0
- Cystic fibrosis treatments may have unseen long-term benefits Jul 16, 2009 | not rated yet | 0
- Severity of cystic fibrosis may be determined by presence of newly-identified modifier genes May 25, 2011 | not rated yet | 0
- Researchers take first step to create cystic fibrosis model using pigs Mar 07, 2008 | not rated yet | 0
- Motion perception revisited: High Phi effect challenges established motion perception assumptions Apr 23, 2013 | 3 / 5 (2) | 2
- Anything you can do I can do better: Neuromolecular foundations of the superiority illusion (Update) Apr 02, 2013 | 4.5 / 5 (11) | 5
- The visual system as economist: Neural resource allocation in visual adaptation Mar 30, 2013 | 5 / 5 (2) | 9
- Separate lives: Neuronal and organismal lifespans decoupled Mar 27, 2013 | 4.9 / 5 (8) | 0
- Sizing things up: The evolutionary neurobiology of scale invariance Feb 28, 2013 | 4.8 / 5 (10) | 14
How can there be villous adenoma in colon, if there are no villi there
9 hours ago As title suggest. Thanks :smile:
How can there be a term called "intestinal metaplasia" of stomach
May 21, 2013 Hello everyone, Ok Stomach's normal epithelium is simple columnar, now in intestinal type of adenocarcinoma of stomach it undergoes "intestinal...
Pressure-volume curve: Elastic Recoil Pressure don't make sense
May 18, 2013 From pressure-volume curve of the lung and chest wall (attached photo), I don't understand why would the elastic recoil pressure of the lung is...
If you became brain-dead, would you want them to pull the plug?
May 17, 2013 I'd want the rest of me to stay alive. Sure it's a lousy way to live but it beats being all-the-way dead. Maybe if I make it 20 years they'll...
MRI bill question
May 15, 2013 Dear PFers, The hospital gave us a $12k bill for one MRI (head with contrast). The people I talked to at the hospital tell me that they do not...
Ratio of Hydrogen of Oxygen in Dessicated Animal Protein
May 13, 2013 As an experiment, for the past few months I've been consuming at least one portion of Jell-O or unflavored Knox gelatin per day. I'm 64, in very...
- More from Physics Forums - Medical Sciences
More news stories
The human gut is loaded with commensal bacteria – "good" microbes that, among other functions, help the body digest food. The gastrointestinal tract contains literally trillions of such cells, and yet the ...
Medical research 3 hours ago | 5 / 5 (1) | 0 |
Swiss scientists reveal the mechanism responsible for aging hidden deep within mitochondria—and dramatically slow it down in worms by administering antibiotics to the young.
Medical research 3 hours ago | 4.5 / 5 (2) | 0 |
On May 22, JoVE will publish details of a technique to measure the health of human genetic material in relation to a patient's age. The method is demonstrated by the laboratory of Dr. Gil Atzmon at New York's Albert Einste ...
Medical research 6 hours ago | not rated yet | 0
(Medical Xpress)—Scientists supported by the National Institutes of Health have a new theory as to why a woman's fertility declines after her mid-30s. They also suggest an approach that might help slow ...
Medical research 8 hours ago | not rated yet | 0 |
Medical researchers discover new ways to target, develop and design drugs to prevent and treat viral infection
Researchers at the University of Alberta have discovered a new drug target, developed a new drug and identified a new way to design drugs—all of which could be a winning combination in the battle against viruses.
Medical research 8 hours ago | 4 / 5 (1) | 0 |
(HealthDay)—Migraines and depression can each cause a great deal of suffering, but new research indicates the combination of the two may be linked to something else entirely—a smaller brain.
15 minutes ago | not rated yet | 0 |
A new approach for immunizing against influenza elicited a more potent immune response and broader protection than the currently licensed seasonal influenza vaccines when tested in mice and ferrets. The vaccine ...
1 hour ago | not rated yet | 0 |
Until now, little was scientifically known about the human potential to cultivate compassion—the emotional state of caring for people who are suffering in a way that motivates altruistic behavior.
39 minutes ago | not rated yet | 0 |
A man who had contracted the coronavirus has died in Saudi Arabia, raising the death toll in the kingdom from the SARS-like virus to 17, the health ministry announced on its website on Wednesday.
33 minutes ago | not rated yet | 0
GlaxoSmithKline PLC says it's starting an unusual collaboration with the U.S. government to develop several antibiotics for both bioterrorism threats and bacterial infections resistant to current medicines.
32 minutes ago | not rated yet | 0
What effect does a father's depression have on his young son or daughter? When fathers report a high level of emotional intimacy in their marriage, their children benefit, said a University of Illinois study.
1 hour ago | not rated yet | 0